Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.
Hareer FatimaHussain Sohail RangwalaMuhammad Saqlain MustafaMuhammad Ashir ShafiqueSyed Raza AbbasAzra RizwanTagwa Kalool Fadlalla AhmedAinan ArshadPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2023)
Danuglipron demonstrates potential for glycemic control and weight reduction in T2DM. Adverse outcomes include diarrhea, nausea, vomiting, and decreased appetite, with dose-related effects. Clinicians must weigh benefits against side effects when considering Danuglipron for T2DM management.
Keyphrases
- irritable bowel syndrome
- glycemic control
- type diabetes
- weight loss
- blood glucose
- small molecule
- end stage renal disease
- insulin resistance
- chronic kidney disease
- newly diagnosed
- ejection fraction
- cardiovascular disease
- prognostic factors
- body mass index
- chemotherapy induced
- body weight
- metabolic syndrome
- weight gain
- adipose tissue
- risk assessment
- human health
- drug induced
- clostridium difficile